Suppr超能文献

肝硬化患者血清对大肠杆菌的杀菌活性不足。

Deficient serum bactericidal activity against Escherichia coli in patients with cirrhosis of the liver.

作者信息

Fierer J, Finley F

出版信息

J Clin Invest. 1979 May;63(5):912-921. doi: 10.1172/JCI109391.

Abstract

The serum bactericidal activity (SBA) of cirrhotic patients was compared with that of normal individuals using the release of (51)Cr from radiolabeled Escherichia coli as the assay method. 80% (22/27) of patients were found to have deficient SBA against at least one of three smooth, serum-sensitive test strains of E. coli. Cirrhotic patients were found to have normal levels of serum lysozyme. Although some patients were mildly hypocomplementemic, this abnormality did not correlate with the presence of a bactericidal defect. Bactericidal antibody in normal and cirrhotics' sera was limited to the immunoglobulin (Ig)M class. Purified IgM from patients with deficient SBA against E. coli 0111 had lower concentrations of bactericidal antibody for that E. coli than did IgM from normal sera; the calculated bactericidal activity of total serum IgM was also lower. The bactericidal defect in cirrhotic serum could be completely corrected by either human antiserum to the homologous strain of E. coli or by purified, normal human IgM. However, because higher concentrations of IgM were required to restore normal SBA to a cirrhotic's serum than to agammaglobulinemic serum, there may be an inhibitor of bactericidal antibody in addition to a deficiency of bactericidal IgM antibody to E. coli in the serum of patients with cirrhosis. The bactericidal activity of the alternative complement pathway was also assessed. Sera from cirrhotic patients had no deficit in SBA attributable to the alternative complement pathway. In fact, in some, the activity of the alternative complement pathway was supernormal, compensating in part for the deficit in IgM-mediated SBA.

摘要

采用放射性标记的大肠杆菌释放(51)Cr作为检测方法,比较了肝硬化患者与正常个体的血清杀菌活性(SBA)。发现80%(22/27)的患者对三种光滑的、血清敏感的大肠杆菌测试菌株中的至少一种具有SBA缺陷。发现肝硬化患者的血清溶菌酶水平正常。虽然一些患者有轻度补体减少,但这种异常与杀菌缺陷的存在无关。正常人和肝硬化患者血清中的杀菌抗体仅限于免疫球蛋白(Ig)M类。对大肠杆菌0111具有SBA缺陷的患者的纯化IgM,其针对该大肠杆菌的杀菌抗体浓度低于正常血清中的IgM;计算得出的总血清IgM的杀菌活性也较低。肝硬化血清中的杀菌缺陷可以通过人抗同源大肠杆菌菌株血清或纯化的正常人IgM完全纠正。然而,由于将肝硬化患者血清的SBA恢复正常所需的IgM浓度高于无丙种球蛋白血症血清,因此除了肝硬化患者血清中针对大肠杆菌的杀菌IgM抗体缺乏外,可能还存在杀菌抗体的抑制剂。还评估了替代补体途径的杀菌活性。肝硬化患者的血清在由替代补体途径引起的SBA方面没有缺陷。事实上,在一些患者中,替代补体途径的活性超常,部分补偿了IgM介导的SBA的缺陷。

相似文献

引用本文的文献

5
Gut microbiome and liver disease.肠道微生物群与肝脏疾病
Transl Res. 2017 Jan;179:49-59. doi: 10.1016/j.trsl.2016.07.005. Epub 2016 Jul 15.

本文引用的文献

2
Precise standardization of reagents for complement fixation.补体结合反应试剂的精确标准化
Am J Trop Med Hyg. 1963 Jan;12:103-16. doi: 10.4269/ajtmh.1963.12.103.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验